Reproductive toxicity studies in pregnant rhesus monkeys and golden Syrian hamsters demonstrated an increase in fetal loss in hamsters treated with Interferon alfacon-1 at doses of > 150 mcg/kg/day, and in rhesus monkeys at doses of 3 and 10 mcg/kg/day. The Interferon alfacon-1 toxicity profile described is consistent with the known toxicity profile of other alpha interferons.
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This protein has a molecular weight of 19,434 daltons.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfacon-1. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfacon-1. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfacon-1. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfacon-1. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfacon-1. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfacon-1. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfacon-1. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfacon-1. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Interferon alfacon-1. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfacon-1. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1. |
| Rituximab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept. |
| Efalizumab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b. |
| Daclizumab | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flunisolide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bortezomib. |
| Cladribine | Interferon alfacon-1 may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carmustine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Amsacrine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludarabine. |